Attovia Secures $265 Million in Latest Series C Funding Round

Attovia secured $265 million in its latest Series C, adding another data point to the Healthcare & Life Sciences funding market.

Attovia Raises $265 million in Funding

Attovia raises $265m in upsized IPO for trials. It operates as a Developer of antibody-based therapeutics for immune-mediated diseases and oncology.

Investors Behind the Funding

The round was backed by Goldman Sachs Asset Management. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Attovia operates in Healthcare & Life Sciences. Attovia's financing adds to recent private-market activity.

Strategic Use of Funds

Fund Phase II trials for ATTO-1310.

Looking Ahead

Attovia raises $265m in upsized IPO for trials

Source reference: original announcement/article.